DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Schwarz Pharma, Incorporated Nitroglycerin Transdermal System; Proposal To Withdraw Approval of One New Drug Application and Five Abbreviated New Drug Applications; Opportunity for a Hearing	)	**Docket No. 77N-0240** **ANDA Nos. 88-727 and 89-022** **DESI No. 1786**

WITHDRAWAL OF HEARING REQUEST
MADE ON BEHALF OF SCHWARZ PHARMA, INCORPORATED

The Federal Register published Thursday, March 25, 1999, contained a Notice proposing to withdraw approval of one new drug application ("NDA") and five abbreviated new drug applications ("ANDA") for nitroglycerin in a transdermal system. Schwarz Pharma, Incorporated is the owner of the ANDAs for DEPONIT®, release rate of 0.2 mg of nitroglycerin per hour (ANDA 88-727) and DEPONIT®, release rate of 0.4 mg of nitroglycerin per hour (ANDA 89-022), both of which are identified in the Notice as subject to Food and Drug Administration's ("FDA") withdrawal proposal.

On April 21, 1999, the undersigned, on behalf of Schwarz Pharma, Incorporated ("Schwarz Pharma"), submitted a timely request for hearing in accordance with the March 25, 1999 Notice and FDA regulations set forth at 21 C.F.R. § 314.200(c)(1)(i). This request for hearing and the submissions made in support of it are hereby withdrawn as of this date.

Richard S. Morey
Peter R. Mathers
Jennifer A. Davidson

KLEINFELD, KAPLAN & BECKER
1140 Nineteenth Street, N.W.
Washington, D.C. 20036
(202) 223-5120

Date: July 17, 2002

Counsel For Schwarz Pharma, Incorporated

77N-0240

WDL9



FIRST CLASS MAIL

KLEINFELD, KAPLAN AND BECKER
SUITE 900
1140 NINETEENTH STREET, N.W.
WASHINGTON, D.C. 20036-6606

TO:

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane
Room 1061
Rockville, MD 20852